TheraRadar
Clinical-Stage Companies / NewAmsterdam Pharma

NewAmsterdam Pharma

Pre-Approval PRO BETA
19
Total Trials
6
Phase 3
7
Phase 2
6
Recruiting
174
Score

Pipeline by Phase

Phase 3
6
Phase 2
7
Phase 1
6

Therapeutic Focus

Dyslipidemias Hypercholesterolemia High Cholesterol Familial Hypercholesterolemia Healthy Volunteers

Clinical Trials (19)

NCT07219602 Phase 3 RECRUITING

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Started: 12/11/2025

NCT06305559 Phase 3 ACTIVE NOT RECRUITING

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

Started: 5/16/2024

NCT06005597 Phase 3 COMPLETED

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Started: 3/1/2024

NCT05142722 Phase 3 COMPLETED

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

Started: 12/15/2021

NCT05425745 Phase 3 COMPLETED

Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

Started: 7/25/2022

NCT05202509 Phase 3 ACTIVE NOT RECRUITING

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Started: 2/7/2022

NCT06496243 Phase 2 RECRUITING

Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels

Started: 12/2/2024

NCT06982508 Phase 2 RECRUITING

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

Started: 9/9/2025

NCT05161715 Phase 2 COMPLETED

Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

Started: 1/12/2022

NCT05421078 Phase 2 COMPLETED

A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

Started: 6/27/2022

NCT04753606 Phase 2 COMPLETED

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Started: 2/18/2021

NCT05266586 Phase 2 COMPLETED

Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

Started: 3/9/2022

NCT04770389 Phase 2 COMPLETED

Randomized Study of Obicetrapib in Combination With Ezetimibe

Started: 2/23/2021

NCT06081166 Phase 1 COMPLETED

A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin

Started: 11/11/2023

NCT06547359 Phase 1 COMPLETED

A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects

Started: 10/1/2024

NCT06250205 Phase 1 COMPLETED

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Started: 2/5/2024

NCT06048302 Phase 1 COMPLETED

PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function

Started: 11/30/2023

NCT05972278 Phase 1 ACTIVE NOT RECRUITING

Investigating the Effect of Obicetrapib on Lipoprotein Metabolism

Started: 12/1/2023

NCT06050291 Phase 1 COMPLETED

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Started: 1/20/2024

Drug Candidates

obicetrapib 10 mg + ezetimibe 10 mg FDC daily obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks Obicetrapib 10 mg Obicetrapib 10mg Placebo Monotherapy obicetrapib Monotherapy ezetimibe Obicetrapib Atorvastatin Calcium Rosuvastatin Calcium
Activity Status: Active
Last Trial Started: 12/11/2025
Last Trial Ended: 11/12/2024
Trials (12 months): 2
Completed Trials: 13
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.